Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HVTN 505: HIV DNA/rAd5 Vaccine Efficacy Trial
NCT00865566Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2009
- Primary completion
- Oct 2017
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VRC-HIVDNA016-00-VP and VRC-HIVADV014-00-VP in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: HIV-1 Infections Diagnosed After Day 0, Participant Dropout at Month 48 and 2 more. Started May 2009; status: terminated.
02
Drugs
VRC-HIVDNA016-00-VPVRC-HIVADV014-00-VP
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00865566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00865566.